Company intelligence / Profile preview
Vincerx
San Mateo, California, United Statesvincerx.com ↗
- Ownership
- Public · VINC
- Employees
- ~13
- Development stage
- Other
01
Overview
Lead clinical program is a highly selective oral and IV CDK9 inhibitor in Phase 1 trials for hematologic malignancies, with signs of clinical activity reported in double-hit DLBCL. Preclinical work is ongoing in SMDCs for solid tumors and ADCs for B-cell malignancies and AML.
- Therapeutic areas
- OncologyHematology
- Modalities
- Small moleculeAntibody-drug conjugateSmall Molecule Drug ConjugateAntibody
- Industry
- Biotech
02
Drug pipeline
10 assets9 more assets in the full pipeline.
03
Partnerships
Bayer (support in start-up phase)
04
Financials
- Market cap
- $78.5K
- Total revenue
- $0
- Enterprise value
- $-4.4M
Beyond the preview
Go deeper on Vincerx.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vincerx.